Alternative strategies for anti-hiv treatment

AIDS

Volumn 15, Issue SUPPL. 5, 2001, Pages

  Eron J J , Jr ^a   Vernazza, P ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretrovirals; Drug development; Therapeutic vaccination; Therapy

Indexed keywords

2' DEOXY 3' OXA 4' THIOCYTIDINE; 6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; ADEFOVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; BETA DEXTRO 2,6 DIAMINOPURINE DIOXOLANE; CAPRAVIRINE; DAPIVIRINE; DIDANOSINE; DPC 681; DPC 684; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SPD 754; STAVUDINE; TENOFOVIR; TENOFOVIR ISOPROXIL FUMARATE; TIPRANAVIR; TMC 126; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CHRONOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS CELL INTERACTION; VIRUS MUTATION;

AIDS VACCINES; ANTI-HIV AGENTS; DRUG DESIGN; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035666815     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200100005-00020     Document Type: Review

References (106)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
3. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
4. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society - USA Panel
5. Panel on Clinical Practices for the Treatment of HIV Infection: DHHS Guidelines
6. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
7. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society - USA Panel
8. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
9. Antiretroviral drug susceptibility and response to initial therapy among recently HIV-infected subjects in North America
10. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
11. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
12. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy
13. Quantifying residual HIV-1 replication in patients receiving combination anti-retroviral therapy
14. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
15. Viral reservoirs and ongoing virus replication in patients on HAART: Implications for clinical management
16. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy
17. Residual HIV RNA and DNA in lymph node, and HIV RNA in genital secretions and in CSF after two years of suppression of viremia in the Merck 035 cohort
18. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides
19. A phase I/II randomized, controlled study of FTC versus 3TC in HIV-infected patients
20. Two randomized, controlled, equivalence trials of emtricitibine (FTC) to lamivudine (3TC)
21. Once-daily combination therapy with emtricitabine, didanosine and efavirenz in treatment-naive HIV-infected adults: 64-Week follow-up of the ANRS 091 Trial
22. Anti-HIV activity and tolerability of DAPD, a novel dioxolane guanosine RT inhibitor: Initial results of a phase I/II 14-day monotherapy clinical trial
23. Clinical HIV suppression after short term monotherapy with DAPD
24. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial
25. Tenofovir disoproxil fumarate (TDF) for the treatment of antiretroviral experienced patients. A double blind, placebo-controlled study
26. HIV-1 RT mutations in patients after 24 weeks of tenofovir disoproxil fumarate (formerly PMPA prodrug) therapy added to stable background ART
27. Short-course monotherapy with AG1549, a novel nonnucleoside reverse transcriptase inhibitor (NNRTI), in antiretroviral naïve patients
28. Antiviral activity and resistance profile of AG1549, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor
29. TMC120 (R147681), a next-generation NNRTI, has potent in vitro activity against NNRTI-resistant HIV variants
30. TMC120, a new non-nucleoside reverse transcriptase inhibitor, is a potent antiretroviral in treatment naive, HIV-1 infected subjects
31. New second generation NNRTIs: Improved resistance and cross-resistance profiles
32. Second generation NNRTIs require multiple mutations for selection of highly resistant HIV in vitro
33. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV infection: 48 Week efficacy and safety results
34. Efficacy of ABT-378/r vs nelfinavir (NFV) in antiretroviral (ARV)-naïve subjects: Results of a phase III blinded randomized clinical trial
35. ABT-378/ritonavir (ABT-378/r) suppresses HIV RNA to ≤400 copies/ml in 84% of PI-experienced patients at 48 Weeks
36. ABT-378/ritonavir (ABT-378/r) and efavirenz: 24 Week safety/efficacy evaluation in multiple PI experienced patients
37. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
38. Patterns of protease inhibitor cross-resistance in viral isolates with reduced susceptibility to ABT-378
39. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples
40. The safety, efficacy and viral dynamics analysis of tipranavir, a new-generation protease inhibitor, in a phase II study in antiretroviral-naive HIV-1-infected patients
41. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632
42. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents
43. Phase II 24-week data from study AI424-008: Results of BMS-232632, stavudine, lamuvidine as HAART for treatment-naïve HIV-infected patients
44. Amprenavir (APV) 600 mg/ritonavir (RTV) 100 mg BID or APV 1200 mg/RTV 200 mg QD given in combination with abacavir (ABC) and lamivudine (3TC) maintains efficacy in ART-naive HIV-1-infected adults over 12 weeks (APV20001)
45. GW433908, a novel prodrug of the HIV protease inhibitor (PI) amprenavir (APV): Safety, efficacy, and pharmacokinetics (PK) (APV20001)
46. DPC 681 and DPC 684: Resistance and cross-resistance profiles of second generation HIV protease inhibitors
47. Structure based design: Novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors
48. A femtomolar HIV-1 protease inhibitor with subnanomolar activity against multidrug resistant HIV-1 strains
49. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial
50. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults
51. Recombinant CD4-IgG2 in human immunodeficiency virus type 1 infected children: Phase 1/2 study
52. Comparative and combinatorial analysis of the HIV-1 entry inhibitors PRO 542, T-20 and PRO 140
53. Mechanisms of synergy between HIV-1 attachment, coreceptor and fusion inhibitors
54. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells
55. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist
56. Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: In vitro studies of mixed virus infections
57. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
58. Inhibiting HIV-1 subtype C viruses
59. A small molecule antagonist of CCR5 that effectively inhibits HIV-1-potential as a novel antiretroviral agent
60. Development of CCR5 antagonists as a new class of anti-HIV therapeutic
61. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS
62. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor
63. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers
64. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry
65. A study of anti-HIV compounds which interfere the virus entry via coreceptor CXCR4
66. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs
67. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
68. Safety, pharmacokinetics, and antiviral activity of T-20 as a single agent in heavily pre-treated patients
69. Forty eight week analysis of patients receiving T-20 as a component of multidrug salvage therapy
70. A controlled phase II trial assessing three doses of T-20 in combination with abacavir, amprenavir, low dose ritonavir and efavirenz in non-nucleoside naïve protease inhibitor experienced HIV-1 infected adults
71. Characterization of genotypic changes in Gp41 ectodomain from patients receiving the fusion inhibitor T-20
72. T1249, a second generation hybrid synthetic peptide inhibitor of HIV: Isolates from T20-treated patients are sensitive to T1249
73. A 14-day assessment of the safety, pharmacokinetics, and antiviral activity of T-1249, a peptide inhibitor of membrane fusion
74. In vitro synergy observed between the fusion inhibitor T-20 and a CCR5 inhibitor TAK-779
75. Multimeric CD4 and coreceptor binding is required to activate HIV-1 envelope protein trimers
76. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells
77. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
78. CD4+effector/memory T Cells as a preferential target for HIV-1 during primary infection
79. HIV type 1-specific helper T cells: A critical host defense
80. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
81. Biological and virologic characteristics of primary HIV infection
82. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
83. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
84. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
85. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug
86. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir
87. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
88. State of the art lecture and summary
89. Immune control of HIV-1 after early treatment of acute infection
90. Control of SIV rebound through structured treatment interruptions during early infection
91. Intervention with quadruple HAART [combivir (COM)/abacavir (ABC)/amprenavir (APV)] intervention during primary HIV-1 infection (PHI) is associated with rapid viremia clearance and decrease of immune activation
92. Effect of Cyclosporin A in combination with highly active antiretroviral therapy in primary HIV-1 infection
93. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals
94. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution
95. Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression
96. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
97. HIV dynamics and HIV-specific CD8+T cells response after three structured treatment interruptions (STI) of antiretroviral treatment (ART) in chronic HIV-infected patients
98. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption
99. Distinct outcomes to multiple treatment interruptions in chronic infection
100. SSITT: A prospective trial of strategic treatment interruptions in 128 patients
101. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214
102. Immunomodulation of chronic HIV-1 infection: Impact of HAART, interleukin-2 and/or an inactivated gp120-depleted HIV-1 immunogen (REMUNE)
103. HIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant
104. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 × 10(6)/L CD4 cell counts: A randomized controlled trial
105. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: A randomised double-blind placebo-controlled trial
106. Safety and immunogenicity study of vCP1452/rgp160 therapeutic vaccines in patients treated with HAART for over two years